GlassScriptPhysician profile
Monique A Richardson
NPI 1619969110
$2,026.33
in general payments reported to CMS, 2019-2025
32 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $198 · 2021: $450 · 2022: $230 · 2023: $228 · 2024: $136 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $293.21 | 2021-2025 | |
| Glaxosmithkline, LLC. | $178.17 | 2019-2024 | Bexsero |
| Pfizer INC. | $130.04 | 2019-2021 | |
| Novo Nordisk INC | $129.91 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $118.59 | 2021-2025 | Airsupra |
| Amarin Pharma, INC. | $115.98 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $111.48 | 2025 | Rexulti |
| Medtronic, INC. | $104.97 | 2022 | |
| Astellas Pharma US INC | $90.47 | 2019-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $83.24 | 2020-2024 | Ajovy |
| Exact Sciences Corporation | $66.99 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $65.96 | 2019-2020 | |
| Lilly USA, LLC | $55.27 | 2020-2023 | Mounjaro |
| Cranial Technologies, INC | $53.63 | 2019-2025 | Doc Band |
| Sanofi Pasteur INC. | $53.18 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $50.23 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.49 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.88 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $26.41 | 2022 | |
| Corcept Therapeutics | $19.10 | 2025 | Korlym |
| Organon LLC | $18.49 | 2021 | |
| Ibsa Pharma INC. | $18.24 | 2023 | Tirosint, Licart |
| Biohaven Pharmaceuticals, INC. | $17.45 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.70 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.43 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.22 | 2020 | |
| Merck Sharp & Dohme LLC | $15.91 | 2022 | |
| Abbott Laboratories | $14.50 | 2021 | |
| Shire North American Group INC | $13.73 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.77 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.